Randomized clinical trial of latanoprot and unoprotone in patient with elevated intraocular preure

To compare the intraocular preure (IOP)-lowering effect and afety of latanoprot 0.005% once daily with that of unoprotone 0.15% twice daily for patient with primary open-angle glaucoma or ocular hypertenion. Deign Randomized clinical trial. Method In a propective, 8-week, invetigator-maked, parallel-group tudy conducted at numerou center in the United tate, 165 previouly treated patient with IOP ≥ 25 mm Hg in one or both eye after wahout were randomly aigned to receive either latanoprot 0.005% once daily in the evening or unoprotone 0.15% twice daily. Obervation procedure were Goldmann applanation tonometry, bet-corrected viual acuity, lit lamp biomicrocopy, and ophthalmocopy. The main outcome meaure wa change in the mean of the IOP meaured at 8:00 , 12 noon, and 4:00 between baeline (before treatment) and after 8 week of treatment. Reult The change in the mean ± D of the IOP meaured at 8:00 , 12 noon, and 4:00 wa −7.2 ± 3.2 mm Hg (28%) for latanoprot (25.3 ± 2.8 mm Hg at baeline to 18.2 ± 2.8 mm Hg at 8 week) and −3.9 ± 2.6 mm Hg (15%) for unoprotone (25.5 ± 3.3 mm Hg at baeline to 21.6 ± 4.0 mm Hg; P ≤ .001. No eriou advere event related to either medication wa reported. Concluion Over an 8-week period, latanoprot 0.005% once daily lowered IOP more than unoprotone 0.15% twice daily in patient with elevated IOP. Both agent were afe and well tolerated.